TP53 and diffuse large B-cell lymphoma: In a study in DLBCL cases, investigators found that the co-occurrence of TP53 mutations and miR-34a methylation was associated with a significantly poor prognosis, with a median survival of 9.4 months (p < 0.0001), whereas single alterations in TP53 or miR-34a/b/c promoter methylation did not impact survival [105].